LP
CLDX icon

LMR Partners’s Celldex Therapeutics CLDX Stock Holding History

LMR Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200,000
Closed -$8.39M – 1129
2024
Q1 		$8.39M Buy
+200,000
New +$8.21M 0.09% 212
2021
Q2 		– Sell
-25,352
Closed -$522K – 1150
2021
Q1 		$522K Buy
+25,352
New +$582K 0.01% 616
2018
Q4 		– Sell
-1,363
Closed -$9K – 356
2018
Q3 		$9K Sell
1,363
-25,893
-95% -$181K ﹤0.01% 340
2018
Q2 		$206K Buy
+27,256
New +$364K 0.01% 415

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LMR Partners's CLDX Position: Q2 2024 in Review

LMR Partners sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 200,000 shares — an estimated $8.39M sold.

LMR Partners first reported a position in CLDX in Q2 2018 and held it in 4 quarters. The position peaked at $8.39M in Q1 2024. 183 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

  • LMR Partners reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
  • LMR Partners sold 200,000 Celldex Therapeutics shares in Q2 2024, an estimated $8.39M.
  • LMR Partners first reported a position in Celldex Therapeutics in Q2 2018 and held it in 4 quarters.
  • LMR Partners's Celldex Therapeutics position peaked at $8.39M in Q1 2024.
  • 183 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.